Drug discovery is a protracted and financially demanding process, making it imperative to pursue the most efficient strategy. To develop effective treatments for mitochondrial diseases, comprehensive drug screening services encompassing diverse models and approaches are essential. Protheragen offers professional and state-of-the-art research services to facilitate the exploration of your drug screening's potential and expedite drug development in mitochondrial diseases.
Introduction to Drug Screening
Drug Screening has increasingly been utilized in the field of pharmaceutics for novel drug discovery. This process involves assaying and screening a vast number of biological effectors and modulators against designated and exclusive targets. Drug Screening encompasses several essential steps, including target recognition, compound management, reagent preparation, assay development, as well as the actual screening itself. By combining Drug Screening with multi-well cell-based platforms, it becomes possible to identify small molecule modulators associated with related biochemical and signal transduction pathways.
Fig.1 Overview of high-throughput screening approach in models of mitochondrial disease. (Falk M. J., 2021)
Our Services
Protheragen specializes in providing state-of-the-art drug screening services tailored to address the intricacies of mitochondrial disease. By leveraging a multidisciplinary approach encompassing biochemical, cell-based, and in vivo assays, we offer comprehensive solutions to expedite the discovery and development of innovative therapeutics targeting mitochondrial dysfunction.
Biochemical Drug Screening
- Utilize purified target proteins to measure ligand binding or enzymatic activity.
- Allow screening of compounds against known targets.
- Useful for determining molecular mechanisms of action.
- Require validation of predicted targets in disease phases.
Cell-Based Drug Screening
- Utilize whole pathways for investigation generating numerous potential points of interest.
- Provide data on pharmacological activity at specific receptors or intracellular targets.
- Promising for studying cell growth, differentiation, and signaling pathways.
- Useful for examining the influence of small molecules and growth conditions on cell function and physiology.
Animal-Based Drug Screening
- Focus on survival, development, activity, and mitochondrial function.
- Evaluate the effects of drugs on disease progression, symptoms, and physiological markers.
Why Choose Us?
- Model Diversity
We employ a variety of model organisms, including Caenorhabditis elegans(C. elegans), zebrafish, and human cell models, to replicate different facets of mitochondrial diseases. Each model offers distinct advantages in terms of experimental feasibility and physiological relevance.
- Phenotypic Outcome Studies
Our screening prioritizes phenotypic outcomes associated with survival, functionality, and overall well-being, aligning with the clinical manifestations of mitochondrial diseases in humans. This comprehensive approach ensures that identified therapeutics target clinically significant endpoints.
- High-Throughput Screening
We utilize automated experimental analyses to facilitate high-throughput screening of multiple molecules from drug classes or large-scale libraries, enabling parallel evaluation of candidate therapies across diverse mitochondrial disease models and enhancing efficiency and scalability.
By integrating diverse models and high-throughput methodologies, Protheragen offers a comprehensive and systematic approach to drug screening services for mitochondrial diseases. If you are interested in availing our services, please feel free to contact us.
Reference
- Falk M. J. (2021). The pursuit of precision mitochondrial medicine: Harnessing preclinical cellular and animal models to optimize mitochondrial disease therapeutic discovery. Journal of inherited metabolic disease, 44(2), 312–324.
